Research

science Clinical Trials & Research

An overview of the current treatment pipeline, research directions, clinical trials, and sources relevant to m.3243A>G, MELAS, and MIDD.

event Editorial update September 2026
Explanation
visibility Overview article Trial design biotech Therapeutic strategies clinical_notes Clinical trials science Earlier directions description Sources

Where the field stands now

Research into m.3243A>G starts with a practical question: can we help cells make and use energy more effectively? The change affects mitochondria, the parts of cells that help turn food into usable energy. Mitochondria generate much of the cell’s ATP through oxidative phosphorylation and contain a separate mitochondrial genome. Pathogenic mtDNA variants can impair respiratory-chain function and produce multisystem disease. 12

Today, your care is still centred on managing symptoms and looking after the organs affected. Researchers are exploring treatments that might offer more help, but we need well-designed studies to find out whether promising ideas make a real difference. Current care is largely supportive and organ-specific. Mechanistic rationale and exploratory signals require confirmation in controlled clinical outcomes. 3456789

Those studies do not all ask the same question. Some focus on fatigue and muscle function, while others are designed for people with MELAS. That is why a study you hear about may be relevant to some people with m.3243A>G and less relevant to others. Eligibility differs by genotype and phenotype; fatigue/myopathy studies and MELAS trials enrol distinct populations. 101112

The aim is to understand what a treatment could change in everyday life. For example, some studies ask people about fatigue or measure their ability to stand up from a chair. Patient-reported fatigue and sit-to-stand performance are prespecified endpoints in current registry protocols. 1011

As you read about these approaches, it helps to keep two questions in mind: who is this being tested in, and what have we learned so far? A result in one group may not tell us what to expect for everyone with m.3243A>G. Investigational approaches vary in target, population and stage; efficacy cannot be generalised across phenotypes. 131415

science

Why mitochondrial trial design has changed

How a study is designed affects what its results can tell us. How a study is designed affects what its results can tell us.

Small studies and differences between participants make results difficult to interpret. A change in a blood marker may not mean a meaningful improvement in daily life. Heterogeneous phenotypes, small samples and surrogate endpoints limit inference. Clinical benefit should be judged against prespecified patient-relevant outcomes. 161718192021

Some studies measure fatigue and the ability to stand from a chair. These outcomes aim to capture effects that could matter in everyday life. Patient-reported fatigue and sit-to-stand performance are prespecified endpoints in current registry protocols. 1011

Some trials compare treatment periods within the same person. This can help with differences between people, but changes over time and effects persisting into the next period still need careful handling. Crossover designs use within-participant comparisons; period effects, carryover and disease instability remain interpretive limitations. 1222

biotech

The main therapeutic strategies in play

Read each programme as a separate research question. Read each programme as a separate research question.

Phase 3 Sonlicromanol

Redox balance and neuroinflammatory targets

Sonlicromanol is being studied in m.3243A>G disease. Earlier research looked at effects on symptoms and function. Sonlicromanol has undergone a genotype-specific phase 2b clinical programme in m.3243A>G disease. 21

The phase 2b study did not meet its primary attention outcome. Other analyses suggested possible benefits, but need confirmation. The phase 3 KHENERFIN registry lists a placebo-controlled trial measuring fatigue and physical function. The phase 2b primary attention endpoint was not met; secondary, adjusted and extension findings are exploratory. KHENERFIN is a phase 3 placebo-controlled confirmatory programme. 1021

Phase 2b paper KHENERFIN trial
Phase 2 KL1333

NAD+ and metabolic targets

FALCON is testing KL1333 against placebo, measuring fatigue and lower-body function over 48 weeks. This is a study of potential benefit, not an established treatment. The FALCON registry describes 48-week KL1333 versus placebo assessment using fatigue and sit-to-stand outcomes. 11

Entry depends on a confirmed mitochondrial diagnosis and defined fatigue and muscle-related features, among other criteria. A diagnosis alone does not establish eligibility. FALCON has genotype, fatigue, myopathy, functional and stability criteria; the study team determines eligibility. 11

FALCON study Trial listing
Phase 2b Zagociguat

Nitric oxide signalling and brain blood flow

PRIZM tested zagociguat in adults with a genetically and clinically defined MELAS presentation. PRIZM enrolled adults meeting genetic and phenotypic MELAS criteria, including prior stroke-like episodes with compatible imaging. 12

The registry lists PRIZM as completed. Its design compared zagociguat with placebo using fatigue, cognition and safety measures. Completion does not show whether the treatment was effective. PRIZM is registered as completed; its phase 2b crossover design assessed fatigue, cognitive performance and safety. Status is distinct from efficacy evidence. 12

PRIZM trial Sponsor page
Phase 2 TTI-0102

Thiol compounds, glutathione and taurine research

TTI-0102 was studied against placebo in people meeting specific MELAS criteria. The trial assessed function, safety and tolerability. The registered TTI-0102 phase 2 study assessed functional capacity and treatment-emergent adverse events in a selected MELAS population. 23

The registry lists the study as completed. Sponsor announcements and interim analyses should not be read as confirmed clinical benefit; complete results and their limitations need assessment. Completion and interim sponsor reports do not establish efficacy. Interpretation requires complete prespecified analyses and safety results. 23

Phase 2 trial Interim data
lightbulb

The practical takeaway

Drug, dietary and genetic approaches address different questions. Benefits in cells, animals or a small selected group cannot be assumed to apply to all carriers. Translation from preclinical models or selected early-phase cohorts requires genotype-relevant controlled clinical evidence. 131415

Genetic approaches remain experimental. Progress is possible, but neither an experimental result nor a trial listing guarantees a future treatment. Preclinical mitochondrial editing and other investigational approaches retain major delivery, specificity, safety and efficacy uncertainties. 13141528

clinical_notes

Clinical trials

Program Target group Stage / status What it is testing
Sonlicromanol Sonlicromanol 10 Adults with m.3243A>G, defined fatigue and myopathy Adults with m.3243A>G, defined fatigue and myopathy 10 Phase 3; recruiting. Registry checked 10 September 2026; record updated 2026-06-29. NCT06451757 Phase 3; recruiting. Registry checked 10 September 2026; record updated 2026-06-29. NCT06451757 10 52-week placebo comparison; fatigue and sit-to-stand outcomes 52-week placebo comparison; fatigue and sit-to-stand outcomes 10
KL1333 KL1333 11 Adults with selected mtDNA disease, fatigue and myopathy Adults with selected mtDNA disease, fatigue and myopathy 11 Phase 2 (registry classification); recruiting. Registry checked 10 September 2026; record updated 2026-06-26. NCT05650229 Phase 2 (registry classification); recruiting. Registry checked 10 September 2026; record updated 2026-06-26. NCT05650229 11 48-week placebo comparison; fatigue and lower-extremity function 48-week placebo comparison; fatigue and lower-extremity function 11
Zagociguat Zagociguat 12 Adults meeting genetic and clinical MELAS criteria Adults meeting genetic and clinical MELAS criteria 12 Phase 2b; completed. Registry checked 10 September 2026; record updated 2026-07-07. NCT06402123 Phase 2b; completed. Registry checked 10 September 2026; record updated 2026-07-07. NCT06402123 12 Crossover placebo comparison; fatigue, cognition and safety Crossover placebo comparison; fatigue, cognition and safety 12
TTI-0102 TTI-0102 23 People meeting specific MELAS and functional criteria People meeting specific MELAS and functional criteria 23 Phase 2; completed. Registry checked 10 September 2026; record updated 2026-07-24. NCT06644534 Phase 2; completed. Registry checked 10 September 2026; record updated 2026-07-24. NCT06644534 23 Placebo comparison; functional capacity and safety Placebo comparison; functional capacity and safety 23
N-acetylcysteine N-acetylcysteine 24 Adults with m.3243A>G and low brain glutathione Adults with m.3243A>G and low brain glutathione 24 Phase 1; recruiting. Registry checked 10 September 2026; record updated 2026-01-23. NCT05241262 Phase 1; recruiting. Registry checked 10 September 2026; record updated 2026-01-23. NCT05241262 24 Dose escalation; maximum tolerated dose Dose escalation; maximum tolerated dose 24
Autologous mesoangioblasts Autologous mesoangioblasts 25 Selected adults with m.3243A>G myopathy Selected adults with m.3243A>G myopathy 25 Phase 1 (registry classification); completed. Registry checked 10 September 2026; record updated 2024-01-17. NCT05063721 Phase 1 (registry classification); completed. Registry checked 10 September 2026; record updated 2024-01-17. NCT05063721 25 Local intra-arterial cell administration; safety measures Local intra-arterial cell administration; safety measures 25
MIDLOC diet study MIDLOC diet study 22 Selected adults with m.3243A>G disease Selected adults with m.3243A>G disease 22 Dietary intervention; completed. Registry checked 10 September 2026; record updated 2025-01-13. NCT06185790 Dietary intervention; completed. Registry checked 10 September 2026; record updated 2025-01-13. NCT06185790 22 Crossover comparison; personal goals and gut microbiome Crossover comparison; personal goals and gut microbiome 22
info A note of caution

Ask your mitochondrial team about any trial you are considering. Check current eligibility, location, visit burden and risks directly with the study team; a registry may lag local availability. Trial suitability requires individual review of eligibility, clinical stability, logistics and investigational risks, with site confirmation of current availability. 131415

open_in_new Find trials and registries genetics Understand the biology first
science

Earlier and more experimental directions

Early studies often ask whether an approach is feasible or tolerable before testing whether it helps. Early studies often ask whether an approach is feasible or tolerable before testing whether it helps.

High-dose NAC

An early NAC study focuses on tolerability in adults with m.3243A>G and low brain glutathione, an antioxidant measured by a specialised scan. It does not justify starting high-dose NAC yourself. The phase 1 NAC registry specifies m.3243A>G and low MRSI glutathione, with maximum tolerated dose as the primary outcome; clinical efficacy remains unestablished. 24

Autologous mesoangioblast therapy

A small early cell-therapy study investigated injecting a person’s own muscle-related cells into an artery supplying one leg. Its safety and feasibility question is different from proving a lasting improvement or cure. The registered phase 1 autologous mesoangioblast study evaluated intra-arterial delivery to one lower leg and safety measures; the registry does not establish durable clinical efficacy. 25

MIDLOC and nutritional reprogramming

MIDLOC studied a lower-carbohydrate, higher-fat diet in m.3243A>G disease. The registry lists it as completed. A study listing is not a reason to copy the diet without specialist advice. MIDLOC is registered as a completed randomised dietary crossover study. Protocol description and completion status do not establish nutritional efficacy or safety for all carriers. 222627

References

28 sources

Sources for the information on this page.

  1. Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. Research articleDOI↑ Back to text
  2. El-Hattab AW, Adesina AM, Jones J, Scaglia F. (2015). MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular genetics and metabolism. ReviewDOI↑ Back to text
  3. Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. Clinical guidanceDOIFull text↑ Back to text
  4. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. (2012). Treatment for mitochondrial disorders. The Cochrane database of systematic reviews. Systematic reviewDOIFull text↑ Back to text
  5. Barcelos I, Shadiack E, Ganetzky RD, Falk MJ. (2020). Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines. Current opinion in pediatrics. ReviewDOIFull text↑ Back to text
  6. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. (2010). A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle & nerve. Randomised trialDOI↑ Back to text
  7. Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  8. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. (2018). Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. Journal of neurology. Clinical studyDOIFull text↑ Back to text
  9. Stefanetti RJ, Ng YS, Errington L, Blain AP, McFarland R, Gorman GS. (2022). l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review. Neurology. Systematic reviewDOIFull text↑ Back to text
  10. Khondrion BV (2026). KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases (NCT06451757) . Trial registry↑ Back to text
  11. Pharming Technologies B.V. (2026). Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (NCT05650229) . Trial registry↑ Back to text
  12. Tisento Therapeutics (2026). A Phase 2b Study of Zagociguat in Patients With MELAS (NCT06402123) . Trial registry↑ Back to text
  13. Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J. (2025). Therapies for Mitochondrial Disease: Past, Present, and Future. Journal of inherited metabolic disease. ReviewDOIFull text↑ Back to text
  14. Joore IP, Shehata S, Muffels I, Castro-Alpízar J, Jiménez-Curiel E, Nagyova E, Levy N, Tang Z, Smit K, Vermeij WP, Rodenburg R, Schiffelers R, Nieuwenhuis EES, van Hasselt PM, Fuchs SA, Koppens MAJ. (2025). Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoS biology. Research articleDOIFull text↑ Back to text
  15. Barrera-Paez JD, Bacman SR, Balla T, Van Booven D, Gannamedi DP, Stewart JB, Mok B, Liu DR, Lombard DB, Griswold AJ, Nedialkova DD, Moraes CT. (2025). Correcting a pathogenic mitochondrial DNA mutation by base editing in mice. Science translational medicine. Research articleDOI↑ Back to text
  16. Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. Research articleDOIFull text↑ Back to text
  17. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. Research articleDOIFull text↑ Back to text
  18. Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J. (2006). Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain : a journal of neurology. Research articleDOI↑ Back to text
  19. Wan Q, Ding Y, Liu W, Yang K. (2026). Effects of exercise training on skeletal muscle function in patients with mitochondrial myopathy: a systematic review. Frontiers in sports and active living. Systematic reviewDOIFull text↑ Back to text
  20. Horne JT, Allen NE, Paul SS, Walker J, Sue C. (2026). MITO-VATION: Feasibility of a technology-supported structured home exercise program in Mitochondrial Disease. PLOS digital health. Research articleDOIFull text↑ Back to text
  21. Smeitink J, van Es J, Bosman B, Janssen MCH, Klopstock T, Gorman G, Vissing J, Ruiterkamp G, Edgar CJ, Abbink EJ, van Maanen R, Pogoryelova O, Stendel C, Bischoff A, Karin I, Munshi M, Kümmel A, Burgert L, Verhaak C, Renkema H. (2025). Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain : a journal of neurology. Randomised trialDOIFull text↑ Back to text
  22. Radboud University Medical Center (2025). MItochondrial Diabetes LOw Carb- Diet Study (NCT06185790) . Trial registry↑ Back to text
  23. Thiogenesis Therapeutics, Inc. (2026). A Study to Assess TTI-0102 vs Placebo in MELAS Patients (NCT06644534) . Trial registry↑ Back to text
  24. Columbia University (2026). Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels (NCT05241262) . Trial registry↑ Back to text
  25. Maastricht University (2024). MABs Therapy m.3243A>G Mutation Carriers (NCT05063721) . Trial registry↑ Back to text
  26. Zweers H, van Wegberg AMJ, Janssen MCH, Wortmann SB. (2021). Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety. Orphanet journal of rare diseases. Systematic reviewDOIFull text↑ Back to text
  27. Zweers HEE, Kroesen SH, Beerlink G, Buit E, Gerrits K, Dorhout A, van Wegberg AMJ, Janssen MCH, Wortmann SB, Timmers S, Saris CGJ. (2024). Ketogenic diet in adult patients with mitochondrial myopathy. Molecular genetics and metabolism. Clinical studyDOI↑ Back to text
  28. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. (2020). A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. Research articleDOIFull text↑ Back to text

Browse the research library for papers grouped by topic.

Keep exploring

Related pages

Related pages you may find interesting.

arrow_forwardSourcesarrow_forwardResourcesarrow_forwardSupport & Specialist Centersarrow_forwardDaily Lifearrow_forwardSupplementsarrow_forwardAbout
chatGive feedback
favorite Support